latest health care news

26.07.19

NICE approves gynaecological cancer treatment on Cancer Drugs Fund

NICE has approved the use of a medicine, previously used at a later stage in the treatment of advanced ovarian cancer, much earlier in the treatment pathway.

Adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line, platinum-based chemotherapy can now be offered the drug olaparib (commercially called Lynparza), NICE has said in draft final guidance published 26 July.

Patients must have be BRCA mutation positive to be eligible to receive the new treatment.

The medicine, a tablet taken twice a day, will be paid for through the Cancer Drugs Fund only if the conditions of the managed access agreement between the company and NHS England and NHS Improvement for olaparib are followed.

Around 700 patients a year are expected to benefit from this decision.

The use of the Cancer Drugs Fund is needed while further data is collected from an ongoing clinical trial, which so far estimates that olaparib delays disease progression by around three years, compared with the placebo.

Olaparib is a type of drug called a PARP inhibitor and works by preventing the PARP protein in cancer cells from repairing damaged DNA, causing the cancer cells to die.

READ MORE: NICE approves breast cancer drug combination on Cancer Drugs Fund

Meindert Boysen, director of the NICE Centre for Health Technology Evaluation, said: “The availability of olaparib tablets as maintenance therapy is an important development in the management of BRCA mutation-positive advanced ovarian cancer.

“Olaparib is already used for ovarian cancer but is expected to have the greatest benefit when used early, and is considered to have the potential to cure the disease in some people if given before the first recurrence.

“We are pleased that the company has agreed a commercial arrangement for olaparib that will allow it to be made available immediately to people who currently have an unmet need for maintenance treatment.”

John Stewart, NHS director of specialised commissioning, added: “Olaparib has the potential to make a huge impact on the treatment of advanced ovarian cancer, giving patients a better chance of survival.”

Comments

There are no comments. Why not be the first?

Add your comment

 

national health executive tv

more videos >

featured articles

View all News

last word

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad, president of the Association of the British Pharmaceutical Industry (ABPI), sits down with National Health Executive as part of our Last Word Q&A series. Would you talk us throu more > more last word articles >

health service focus

View all News

comment

NHS England dementia director prescribes rugby for mental health and dementia patients

23/09/2019NHS England dementia director prescribes rugby for mental health and dementia patients

Reason to celebrate as NHS says watching rugby can be good for your mental ... more >
Peter Kyle MP: It’s time to say thank you this Public Service Day

21/06/2019Peter Kyle MP: It’s time to say thank you this Public Service Day

Taking time to say thank you is one of the hidden pillars of a society. Bei... more >

interviews

Matt Hancock says GP recruitment is on the rise to support ‘bedrock of the NHS’

24/10/2019Matt Hancock says GP recruitment is on the rise to support ‘bedrock of the NHS’

Today, speaking at the Royal College of General Practitioners (RCGP) annual... more >

the scalpel's daily blog

Providers are delivering – and here’s how

09/10/2019Providers are delivering – and here’s how

It has been a challenging few years for healthcare providers, yet they have continued to deliver high quality care despite the conditions. Adam Brimelow, director of comm... more >
read more blog posts from 'the scalpel' >

editor's comment

25/09/2017A hotbed of innovation

This edition of NHE comes hot on the heels of this year’s NHS Expo which, once again, proved to be a huge success at Manchester Central. A number of announcements were made during the event, with the health secretary naming the second wave of NHS digital pioneers, or ‘fast followers’, which follow the initial global digital exemplars who were revealed at the same show 12 months earlier.  Jeremy Hunt also stated that by the end of 2018 – the 70th birthday... read more >